Rituximab-Based Regimen As First-Line Treatment In Chinese Patients With Follicular Lymphoma: Three-Year Safety Data From A Prospective, Observational Study
BLOOD(2017)
摘要
Background:
更多查看译文
关键词
follicular lymphoma,chinese patients,rituximab-based,first-line,three-year
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要